akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Thursday, December 11, 2014

Company News: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT

-      Dose assessment for upcoming Phase III trial

Anergis, a company developing proprietary ultra-fast allergy vaccines, today announced the start of a Phase II trial designed to finalize the dose selection for the Phase III study of AllerT. AllerT is Anergis´ lead vaccine against birch pollen allergy that originated from the company´s proprietary Contiguous Overlapping Peptide (COP) platform. COPs are pharmaceutical-grade, long-peptide immunotherapeutics designed for an ultra-fast, safe and long-lasting treatment of allergy patients.

The randomized, double-blind, placebo-controlled, 4-parallel-group trial will assess the dose response efficacy of AllerT across doses of 50 µg, 25 µg, 10 µg compared to a placebo in an environmental exposure chamber (EEC). Approximately 180 birch pollen allergy patients will receive 5 subcutaneous injections over 2 months. All enrolled patients will be challenged with birch pollen prior to receiving AllerT or the placebo, and 4 weeks after the last injection.

Wednesday, December 10, 2014

Company News: Heraeus Medical GmbH Signs Exclusive License and Development Agreement with Locate Therapeutics for Orthopaedic Applications

Heraeus Medical GmbH announced today an agreement with Locate Therapeutics to license the intellectual property surrounding the use of TAOS® in orthopaedic applications and the inception of the first development program in this field.  The agreement gives Heraeus Medical GmbH the rights to the future co-developed orthopaedic products as well as the processes involved in manufacturing the final product. Locate Therapeutics has the full capabilities to carry out such development work. The agreement takes the form of a standard upfront and milestone payment structure.